Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade

Niewolik, Jacqueline; Mikuteit, Marie; Cossmann, Anne; Vahldiek, Kai; Gutzmer, Ralf; Müller, Frank; Schröder, Dominik; Heinemann, Stephanie; Behrens, Georg M. N.; Dopfer-Jablonka, Alexandra; Steffens, Sandra; Grimmelmann, Imke

doi:10.1159/000524894

Cited by 5 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the one hand, comparable antibody responses against COVID-19 vaccination were observed between cancer patients with PD-1/PD-L1 ICB therapy and healthy participates [44] , [45] , which hints the restoration of tumor-blunted COVID-19 vaccine effectiveness in patients receiving PD-1/PD-L1 ICB therapy to that of healthy participates. Indeed, cancer patients with PD-1/PD-L1 ICB therapy showed a trend towards increased COVID-19 vaccine effectiveness as compared to that of cancer patients with no therapies [5] , [46] . Otherwise, several studies reported lower COVID-19 vaccine-induced antibody responses in cancer patients receiving PD-1/PD-L1 ICB therapy relative to healthy participants [47] , [48] .…”

Section: Discussionmentioning

confidence: 99%

PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness

Chen

Yue

Yang

et al. 2023

Vaccine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness

Chen

Yue

Yang

et al. 2023

Vaccine

View full text Add to dashboard Cite

“…108 Melanoma patients receiving ICI therapy showed comparable antibody responses after COVID-19 vaccination. 109 Conversely, with mRNA vaccination for COVID-19, patients with lung cancer who received ICI treatment did not have an increased incidence of irAEs. 110,111 Consensus recommendation 10 For cancer patients, it is necessary to decide whether vaccination is appropriate based on various parameters, such as disease severity, treatment stage, and treatment methods.…”

Section: Vaccinated Patientsmentioning

confidence: 98%

Section: Administration Of Icis To Special Populationsmentioning

confidence: 98%

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations

et al. 2023

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly durable clinical benefits and tolerable toxicities and have improved the survival of patients with various types of cancer. Since 2018, the National Medical Products Administration of China has approved 17 ICIs as the standard treatment for certain advanced or metastatic solid tumors. As ICIs represent a broad-spectrum antitumor strategy, the populations eligible for cancer immunotherapy are rapidly expanding. However, the clinical applications of ICIs in cancer patient populations with special issues, a term that refers to complex subgroups of patients with comorbidities, special clinical conditions, or concomitant medications who are routinely excluded from prospective clinical trials of ICIs or are underrepresented in these trials, represent a great real-world challenge. Although the Chinese Society of Clinical Oncology (CSCO) has provided recommendations for screening before the use of ICIs in special populations, the recommendations for full-course management remain insufficient. The CSCO Expert Committee on Immunotherapy organized leading medical oncology and multidisciplinary experts to develop a consensus that will serve as an important reference for clinicians to guide the proper application of ICIs in special patient populations. This article is a translation of a study first published in Chinese in The Chinese Clinical Oncology (ISSN 1009-0460, CN 32-1577/R) in May 2022 (27(5):442–454). The publisher of the original paper has provided written confirmation of permission to publish this translation in Therapeutic Advances in Medical Oncology.

show abstract

“…They also observed a tendency for higher antibody levels when ICI therapy was received within the last six months before vaccination. Moreover, subgroup analysis revealed that patients under ongoing targeted therapy during the vaccination period had significantly higher median antibody levels than patients without any active antitumor treatment [91].…”

Section: Icis and Anti-infectious Vaccinesmentioning

confidence: 99%

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches

et al. 2022

View full text Add to dashboard Cite

In recent years, the use of immune checkpoint inhibitors (ICIs) in combination with approved or experimental vaccines has proven to be a promising approach to improve vaccine immunogenicity and efficacy. This strategy seeks to overcome the immunosuppressive mechanisms associated with the vaccine response, thereby achieving increased immunogenicity and efficacy. Most of the information on the use of ICIs combined with vaccines derives from studies on certain anti-tumor vaccines combined with monoclonal antibodies (mAbs) against either cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death-ligand 1 (PD-L1). However, over the past few years, emerging strategies to use new-generation ICIs as molecular adjuvants are paving the way for future advances in vaccine research. Here, we review the current state and future directions of the use of ICIs in experimental and clinical settings, including mAbs and alternative new approaches using antisense oligonucleotides (ASOs), small non-coding RNAs, aptamers, peptides, and other small molecules for improving vaccine efficacy. The scope of this review mainly includes the use of ICIs in therapeutic antitumor vaccines, although recent research on anti-infective vaccines will also be addressed.

show abstract

Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade

Cited by 5 publications

References 18 publications

PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness

PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches

Contact Info

Product

Resources

About